A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors

Trial Profile

A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs WX 037 (Primary) ; WX 554 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Sponsors Heidelberg Pharma AG
  • Most Recent Events

    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
    • 14 Apr 2014 Status changed from recruiting to discontinued, as reported in a Wilex media release.
    • 07 Aug 2013 Status changed from not yet recruiting to recruiting, according to a WILEX media release. The first patients have been enrolled and dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top